Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
Topic
Thought Leadership
Navigating the impacts of the Inflation Reduction Act (IRA): Strategic considerations for pharma
With a few years now into the enactment of the Inflation Reduction Act (IRA), the law continues its...
Why reliable mortality measurement in real-world evidence matters
Understanding mortality in taXonomy and the importance of post mortem activity This is the third...
When billed and allowed amounts aren’t enough: HealthVerity market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our...
Does your data link?
How clinical data linkage closes evidence gaps in real-world data Clinical data linkage helps...
Why 'good enough' data is risky
Real World Data (RWD) is increasingly being incorporated into healthcare and life science research...
Inside taXonomy, a next-gen closed claims solution for real-world evidence generation
Healthcare claims data are one of the most powerful sources of data in generating real-world...
Rethinking healthcare audience targeting for data-driven precision
Why healthcare marketers need more transparency in audience targeting Healthcare marketers are...
HPV vaccination trends from 2016 to 2025: Progress and missed opportunities
by: Alexandra Miller, MPH Human papillomavirus (HPV) is one of the most common sexually...
The Missing Pieces: How Rare Disease Diagnoses Come Together
Rare diseases may be individually uncommon, but collectively they affect an estimated 30 million...